Trial Profile
A Multicenter, Single-Arm, Open-Label Study to Evaluate the Immunogenicity and Pharmacokinetics of BIIB019, Daclizumab High Yield Process (DAC HYP), Prefilled Syringe Administered by Subcutaneous Injection in Subjects With Relapsing-Remitting Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Daclizumab (Primary) ; Caffeine; Dextromethorphan; Midazolam; Omeprazole; Vitamin K; Warfarin
- Indications Multiple sclerosis
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Acronyms OBSERVE
- Sponsors Biogen
- 01 Mar 2019 Results from case series from multiple clinical trials (205MS203, 205MS301, 205MS302 and 205MS303) published in the Respiratory Medicine
- 19 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 17 Mar 2016 Results (n=20) published in the British Journal of Clinical Pharmacology.